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 The optic neuropathy called glaucoma is the second most
common cause of bilateral blindness in the world [1]. The most
frequent form of glaucoma is open-angle glaucoma (OAG),
which can occur as adult-onset primary open-angle glaucoma
(POAG) or juvenile-onset primary open-angle glaucoma
(JOAG). Prevalence of OAG has been measured at higher fre-
quencies in individuals of African ancestry than in those of
European or Asian ancestry [2]. Although the most common
form of OAG in the US involves elevated intraocular pressure
(IOP), OAG also develops in individuals whose IOP is never
observed outside of the normal range (normal tension glau-
coma, NTG). Associated risk factors for OAG include race
(i.e., population genetic factors, particularly ethnic ancestry),
a family history of glaucoma, increasing age, and an IOP el-
evated above the normal range.
During the last decade, genetic mapping and cloning ex-
periments have demonstrated that glaucoma has substantial
genetic components [3]. Among the more than one dozen
mapped glaucoma loci, 11 GLC1 loci cause OAG [3], two
GLC3 loci cause congenital glaucoma [4,5], and the remain-
ing known loci are responsible for secondary and develop-
mental forms of glaucoma [3]. Additional genetic risk factors
for differential severity of OAG have been reported [3].
Mutations in the myocilin (MYOC) gene at the GLC1A
locus are found in 2.6-4.3% of POAG cases [6] and up to one-
third of the familial JOAG cases [7]. There has not yet been a
follow-up on a recent report that mutations in WD repeat do-
main 36 (WDR36) that occur in cases of POAG that map to
the GLC1G locus on chromosome 5 [8].
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Purpose: To evaluate the extent to which mutations in the optineurin (OPTN) glaucoma gene play a role in glaucoma in
different populations.
Methods: Case-controlled study of OPTN sequence variants in individuals with or without glaucoma in populations of
different ancestral origins and evaluate previous OPTN reports. We analyzed 314 subjects with African, Asian, Caucasian
and Hispanic ancestries included 229 cases of primary open-angle glaucoma, 51 cases of juvenile-onset open-angle glau-
coma, 33 cases of normal tension glaucoma, and 371 controls. Polymerase chain reaction-amplified OPTN coding exons
were resequenced and case frequencies were compared to frequencies in controls matched for ancestry.
Results: The E50K sequence variant was identified in one individual from Chile with normal tension glaucoma, and the
691_692insAG variant was found in one Ashkenazi Jewish individual from Russia. The R545Q variant was found in two
Asian individuals with primary open-angle glaucoma; one of Filipino ancestry and one of Korean ancestry. In addition to
presenting OPTN allele frequencies for Caucasian and Asian populations that have been the subject of previous reports,
we also present information for populations of Hispanic and black African ancestries.
Conclusions: Our study contributes additional evidence to support the previously reported association of the OPTN E50K
mutation with glaucoma. After finding an additional 691_692insAG OPTN variant, we can still only conclude that this
variant is rare. Combined analysis of our data with data from more than a dozen other studies indicates no association of
R545Q with glaucoma in most populations. Those same studies disagree in their conclusions regarding the role of M98K
in glaucoma. Our analysis of the combined data provides statistically significant evidence of association of M98K with
normal tension glaucoma in Asian populations, but not in Caucasian populations; however, the validity of this conclusion
is questionable because of large differences in allele frequencies between and within populations. It is currently not
possible to tell how much of the underlying cause of the allele frequency difference is attributable to demographic, tech-
nical, or ascertainment differences among the studies.
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151Rezaie et al. [9] described mutations in the optineurin
(OPTN) gene, located within the GLC1E interval at 10p15-
p14 [10], in 16.7% of families from a predominantly NTG
population. The original report of OPTN involvement in glau-
coma presented three likely disease-causing variants desig-
nated E50K, 691_692insAG, and R545Q, and one proposed
risk factor M98K [9]. Further studies find association of some
OPTN alleles with OAG, but others report no evidence of as-
sociation of OAG with those same alleles [11-24].
In this paper, we present new data on our OPTN mutation
screening of 314 open-angle glaucoma patients who have ei-
ther POAG, JOAG, or NTG, from populations of Caucasian,
Asian, Hispanic, and African ancestry. We present case re-
ports of individuals with E50K and 691_692insAG mutations
and discuss findings from more than a dozen studies that have
carried out OPTN mutation screening.
METHODS
Subjects:  Informed consent was obtained from each partici-
pant according to a HIPAA-compliant study protocol approved
by The University of Michigan Institutional Review Board
for review of human subjects studies. Ophthalmologic exami-
nations included slit-lamp biomicroscopy, optic disk exami-
nation, IOP by applanation, gonioscopy, and refraction. Indi-
viduals with known surgical or pharmacologic risk factors for
glaucoma, such as steroid use, were excluded from this study.
OAG was diagnosed based on the presence of open fil-
tration angles, glaucomatous optic discs and glaucomatous
visual field changes. Individuals with elevated IOP, greater
than or equal to 22 mmHg, were considered to have POAG if
they showed adult-onset at 35 years of age or older, and to
have JOAG if they showed onset prior to 35 years of age.
They were deemed to have NTG if their highest known IOP
never exceeded 21 mmHg.
Table 1 lists our study case and control subjects by their
diagnosis and ancestry. Our 314 OAG subjects included 51
JOAG, 230 POAG, and 33 NTG cases. Our control samples
came from 371 unrelated individuals. Normal control samples
were matched for race to the cases, so that a sequence variant
found in a particular case population had control screening
carried out only in the control population of the same ances-
try. In most cases, the sample screened was the proband of the
family, but sometimes a different case from that family had to
be used, such as when the proband was someone with an am-
biguous diagnosis. For some families in which the proband
had a sequence variant of interest, additional relatives were
also screened. The group of normal control samples included
samples from 48 individuals of African ancestry (Corielle In-
stitute, Camden, NJ), 19 individuals of Hispanic ancestry, and
99 individuals of Asian ancestry (Corielle Institute) who had
not been characterized for ophthalmologic phenotype. These
uncharacterized population controls were used in a subset of
experiments as detailed in Results.
Mutation Screening:  OPTN was screened via sequencing of
polymerase chain reaction (PCR) amplified DNA. Genomic
DNA was extracted from peripheral blood samples using
Puregene DNA Isolation kits (Gentra Systems, Minneapolis,
MN) following the manufacurer’s protocol. OPTN coding
exons were amplified by PCR in a 20 µl reaction containing
50 ng of genomic DNA, 1.5 mmol/l MgCl2, 0.5 µmol/l of each
primer, 0.125 mmol/l of each dNTP, and 0.5 units of Amplitaq
Gold (PE Applied Biosystems, Foster City, CA) in 1X final
©2007 Molecular Vision Molecular Vision 2007; 13:151-63 <http://www.molvis.org/molvis/v13/a18/>
TABLE 1. ANCESTRY AND DIAGNOSIS OF SUBJECTS
                                                                         Total
                    Population                       JOAG   POAG   NTG    OAG    Control   Total
--------------------------------------------------   ----   ----   ---   -----   -------   -----
   African
(U.S., Ghana, Nigeria, and the Caribbean)             14     63     4      81       88      169
   Asian
(Korea, China, and the Philippines)                    2      1     2       5      117      122
   Caucasian
(Europe and the Middle East)                          32    159    26     217      116      333
   Hispanic
(Mexico, Puerto Rico, Chile, Panama, and Colombia)     3      7     1      11       50       61
Totals                                                51    230    33     314      371      685
The frequency distribution of cases and controls according to open-angle glaucoma (OAG) condition and ancestry (national) in our analysis
included 314 cases with juvenile onset OAG (JOAG), primary open-angle glaucoma (POAG), and normal tension glaucoma (NTG).
TABLE 2. PRIMERS USED FOR SEQUENCING THE OPTN GENE
       Forward primer sequence   Reverse primer sequence
Exon           (5'-3')                   (5'-3')
----   -----------------------   -----------------------
  4    TGGAGAGAAAGTGGGCAACT      CACCAGCTACCACCTATGGA
  5    GGCATCTTTCAATTCAGAGCC     GACACGTAAGATTCCACTGC
  6    TCCCAGAGCTCTGCGATTAA      GCTACACTGGAATTTCCTCA
  7    TCTGAGCCACCCCGTTTAAA      GACCTCCGGTGACAAG
  8    GGAGAATGTTCTGGAAAGCAG     GGGTGAACTGTATGGTATCT
  9    CCCCTGATCCTTTATCCCAA      AATTCAGTGGCTGGACTAC
 10    TGGTTCAGCCTGTTTTCTCC      CCCCCCATCTTACAAGTATTTC
 11    TGGCCAGGTCTAGTGAAGAA      TTTATCCCCCTCTCTGAGAG
 12    GAAATGCTAGTAGGTCGTGG      CCCTGACCATAGGACATTCA
 13    CCGGCCAGAGCTGATAAT        AGATCCACTGAGCACTTTCC
 14    CTAGCAGGATTGTGCATCGT      GTGGCGCGAACACAGCTATT
 15    TTTCCCCTACTTCTGTGGAC      GAGACTGACGGGTGCTATAT
 16    TCATGTCCCACTACGTGTTG      TGTGCCCGGCCTGTTTTCTT
Primers used in amplification of OPTN exons were also used in se-
quencing reactions. Primers located in introns were placed far enough
away from the exon boundaries to allow visualization of the sequence
of the splice sites. Exons 4 through 16 are the exons that contain
coding sequence.
152concentration of the PCR buffer. Primers used for exon am-
plification are listed in Table 2. PCR conditions were 10 min
at 95 °C followed by 36 cycles of 1 min at 95 °C, 1 min at 55
°C, and 1 min at 72 °C with a final extension for 10 min at 72
°C. Sequencing of PCR-amplified DNA was used to screen
all 314 OAG cases for mutations in the coding sequences (i.e.,
exons 4 through 16) and splice sites flanking OPTN exons.
When a sequence variant was detected in a patient, we screened
for that specific mutation in the control population samples of
the same ancestry.
Individuals with E50K and 691_692insAG mutations who
are presented in the case reports were screened for mutations
in MYOC. PCR amplification of the three MYOC exons was
conducted as described in reference [7] with some modified
primers as listed in Table 3. PCR products were purified with
a QIAquick PCR purification kit (Qiagen, Santa Clarita, CA).
Sequenced PCR products were analyzed on an ABI 377 se-
quencer or at the University of Michigan DNA Sequencing
Core facility on either an ABI 3730 or 3700 sequencer.
Statistical Analysis:  Published reports on the frequency
of OAG mutations were compared using several different sta-
tistical tests. Because some studies contained expected fre-
quencies of less than 5, Fisher’s exact test was chosen to ex-
amine the 2x2 contingency tables of individual studies. In tan-
dem with Fisher’s exact test, odds ratios and 95% confidence
intervals for the odds ratio were calculated. To estimate odds
ratios for whole populations based on multiple studies, fixed
effect estimates were calculated using a Mantel-Haenszel (MH)
model [25]. Homogeneity was evaluated with the Woolf test,
in which the p value allows a determination of the appropri-
ateness of combining studies by testing for evidence of effect
modification by study group (i.e., testing whether the odds
ratios are the same in all studies). For a case-control study, an
odds ratio greater than 1 indicates that OAG cases are more
likely to have the gene of interest than controls. For 2x2 con-
tingency tables, independence is equivalent to an odds ratio
of 1. All statistics were computed using the open source sta-
tistical program R 2.3.1 with the packages rmeta 2.12, meta
0.5, and vcd 0.9-7. [26-29]
RESULTS
E50K OPTN mutation in a case with normal tension glau-
coma: Case 1, a 52 year old Chilean female (III:1; Figure 1),
was diagnosed with NTG at age 42 years and her highest pre-
treatment IOP was 18 mmHg in both eyes. After bilateral
trabeculectomies and betaxolol treatment, her IOPs were 6
mmHg in the right eye and 10 mmHg in the left eye. Gonio-
scopic exam revealed open angles in both eyes, with iris pro-
cesses noted circumferentially in both eyes. A dilated fundus-
copic exam demonstrated advanced glaucomatous cupping
with cup-to-disc ratios of 1.0 in both eyes and absence of hem-
orrhage. Sequence changes were absent in the MYOC gene
coding sequence and splice sites. Her family history showed
evidence of autosomal dominant inheritance (Figure 1). The
E50K mutation was found in three of the proband’s four af-
fected relatives that were in the study (II:1, III:2, and III:7;
Figure 1). The E50K mutation was absent in the proband’s
affected aunt (II:3; Figure 1) as well as five unaffected rela-
tives that were screened (Figure 1).
691_692insAG OPTN mutation in a case with primary
open-angle glaucoma: Case 2 was a female Russian Ashkenazi
Jewish immigrant diagnosed with POAG at 80 years of age.
Her ocular history was significant for high myopia (right eye
-17.75 diopters, left eye -19.00 diopters) and myopic retinal
degeneration in both eyes. The patient had a childhood his-
tory of measles, a disease that has been identified as a pos-
sible contributor to high myopia. [30,31] At the time of the
POAG diagnosis, the patient already had dense, 4-quadrant
visual field defects in both eyes, attributable to the retinal de-
generation, or a long-standing undiagnosed glaucoma, or both.
She had cup-to-disc ratios of 0.5 in both eyes and diffuse
chorioretinal atrophy. Her IOPs were 22 mmHg in the right
eye and 21 mmHg in the left eye. Her IOPs decreased to 17
mmHg in the right eye and 16 mmHg in the left eye at one
month after treatment with betaxolol, dipivefrin, and pilo-
carpine. Over the next several years, her IOPs fluctuated be-
tween the low teens and mid-twenties while she underwent
treatment with medication, laser treatments, and multiple
trabeculectomies. Screening of the OPTN gene revealed an
insertion of AG at positions 691 and 692 (691_692insAG) in
one copy of the OPTN gene. There were no other sequence
variants in the coding sequence or splice sites of either OPTN
or MYOC. Little family history information was available. She
had a maternal grandfather affected by high myopia, but she
didn’t know of any other cases of glaucoma in her small fam-
ily. Her only living relative, a reportedly unaffected son, de-
clined to participate in the study.
R545Q and M98K OPTN sequence variants: The R545Q
sequence variant was found in two individuals with OAG. One
woman with Filipino ancestry had JOAG diagnosed at 24 years
of age and had a maximum known pretreatment IOP of 50
mmHg. Her mother also had POAG and her brother is unaf-
fected. She did not know the diagnostic status of the rest of
her relatives in the Philippines. The second case, a Korean
woman diagnosed at 55 years of age, had a maximum known
IOP of 29 mmHg and an unknown family history of glau-
coma.
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TABLE 3. PRIMERS USED FOR SEQUENCING THE MYOC GENE
        Forward primer sequence     Reverse primer sequence
Exon            (5'-3')                     (5'-3')
----   -------------------------   -------------------------
 1A    GGCTGGCTCCCCAGTATATA        CTGCTGAACTCAGAGTCCCC
 1B    AGGCCAATGTCAAGTCATCCAT      CTCCAGAACTGACTTGTCTC
  2    ACATAGTCAATCCTTGGGCC        TAAAGACCACGTGGCACA
 3A    CTGGCTCTGCCAAGCTTCCGCATGA   GGCTGGCTCTCCCTTCAGCCTGCT
 3B    GAGCTGAATACCGAGACAGTGAA     GAGGCCTGCTTCATCCACAGCCAAC
Primers used in amplification of MYOC exons were also used in se-
quencing reactions. Primers located in introns were placed far enough
away from the exon boundaries to allow visualization of the sequence
of the splice sites. Primer pairs 1A, 2, and 3A were used for PCR
amplification and sequencing of exons 1, 2, and 3, respectively. Prim-
ers 1B and 3B are internal primers that were used for sequencing
purposes only.
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Among 36 OAG cases with the M98K mutation, the 26
for whom we have historical IOP data had known maximum
IOPs between 16 mmHg and 55 mmHg (mean=29.6 mmHg).
Out of the 283 OAG cases who lacked the M98K mutation,
253 had historical IOP data available, with the maximum re-
corded IOPs ranging from 14 mmHg up to 77 mmHg
(mean=29.9 mmHg).
OPTN sequence variants in the whole study cohort:
Among the 314 OAG cases, we found a total of four (1.2%)
individuals who possessed any of the three sequence variants
reported by Rezaie and colleagues [9] to be disease-causing
variants (Table 4).
The E50K mutation in Case 1 was the only instance of
E50K among the 314 OAG cases (1/314, 0.3%) and in none
of 371 controls (<2.7%), and was one of only 11 Hispanic
cases screened (1/11, 9.1%; Table 4). E50K was identified in
one of the 33 NTG cases (3.0%), but was not present in the
230 POAG or 51 JOAG cases. This mutation was present in
1/11 (9.1%) Hispanic cases and none of 50 Hispanic controls.
It was also absent from 86 Caucasian normal controls.
The single instance of 691_692insAG in Case 2 was found
among the 314 OAG cases (1/314, 0.3%), and was one of 217
Caucasian OAG cases screened (0.5%; Table 4). This was one
of 230 POAG cases (0.4%) and was not present in 116 Cauca-
sian controls, including seven samples that share Ashkenazi
Jewish ancestry with the case having the mutation. In addi-
tion, 691_692insAG was present in one case in the original
report by Rezeai [9] but that report did not provide informa-
tion on ancestry of that case, so we could not tell whether
their case and our case shared ancestral origins. This mutation
was also previously reported as being absent from 200 normal
control chromosomes of Caucasian origin [9].
R545Q was present in two of the 314 OAG cases (0.6%;
Table 4). It was found once among the 51 JOAG cases (1.9%)
and once among the 33 NTG cases (3.0%). Both instances of
R545Q were found in individuals of Asian ancestry (2/5,
40.0%). R545Q was also present in 11 of 117 (9.4%) controls
of Asian ancestry. The absence of this allele from our Cauca-
sian cases or controls (0/333, <0.3%) concords with previous
reports that failed to find it in either cases or controls of Euro-
pean ancestry (0/1457), suggesting that the allele frequency
in European populations may be less than 0.1%
[9,11,13,22,23,32,33]. Based on our data, we suggest that
R545Q may be of low prevalence in African (<0.6%) or His-
panic populations (<1.6%), but our ability to estimate frequen-
cies in these populations is limited because of sample size.
The M98K sequence variant was found in JOAG, POAG,
NTG, and control populations (Table 5 and Table 6). We ob-
served statistically insignificant differences in the frequencies
between cases and controls for Africans and Caucasians, the
two large sample sets in the study (Table 5). Frequencies in
Asian samples (32/122, 26.2%) resembled values for African
samples (18/81, 22.2%), while frequencies for Hispanic
samples (2/62, 3.2%) seemed more similar to frequencies for
Caucasian samples (8/116, 6.9%), but sample sizes were small.
Additionally, the Asian samples showed no difference between
cases and controls (p value=0.112), but the sample size was
small and the use of a predominantly Chinese population to
control for findings from a mixed Asian case set was prob-
lematic when looking at an allele that showed considerable
variation among populations. Thus, although our overall study
population showed M98K in 36 of 314 OAG individuals
(11.5%) and 58 of 371 controls (15.6%), such pooling of data
from different racial/ethnic groups is invalid where popula-
tion frequencies vary so greatly.
Screening identified two instances of E322K in both cases
and controls - a change previously reported to be associated
with glaucoma [9] (Table 4). We also found silent OPTN cod-
Figure 1. Lack of complete cosegregation of E50K with glaucoma in the pedigree of a Chilean family.  The arrow indicates the proband (Case
1). Filled symbols are affected individuals with NTG, open symbols are individuals who are unaffected or reported to be unaffected. Symbols
with a cross indicate individuals who are glaucoma-suspect, symbols with a center dot indicate glaucoma-affected individuals according to
family report, and partially filled symbols denote individuals affected with POAG. Diagonal lines mark deceased individuals. Individuals
denoted with ++ have E50 alleles on both chromosomes and ones with M+ carry the E50K heterozygous change. Members of generation four
are young enough that they are not expected to be affected yet.
154ing sequence polymorphisms, including L32L, T34T, L41L,
E63E, A134A, and S321S, as well as previously reported
intronic sequence variants [4,10,11,20,24,34,35]. We did not
find Ile88Val or Ala99Ser in our case populations, but did
observe them among our controls (Table 4).
Pooled data on R545Q:  R545Q was present in our Asian
data set, but absent from the other three populations we
screened. We found no significant differences in allele fre-
quencies between cases and controls for R545Q. This agrees
with many of the other published studies, although it should
be noted that Mukhopadhyay et al. [19] did report the case-
control difference to be significant (Table 6). Evaluation of
odds ratios and frequencies for each of the Asian studies
showed no statistically significant differences between case
and control values for any of the Asian data sets (Figure 2,
Table 6). With the exception of the Rezaie study [9], R545Q
has been reported only in Chinese, Japanese, Korean, Fili-
pino, Indian, and mixed-ancestry populations (Table 6).
Our Asian data set is small, so we examined the possibil-
ity of pooling data from multiple studies. Because of observed
variation in allele frequencies among studies (0.6-6.8%; Table
6), we questioned whether the data could be validly combined.
Using the Woolf test for heterogeneity to address this ques-
tion, we found no statistically significant study-based stratifi-
cation within the individual populations for R545Q (Table 7).
This means that it is reasonable to take data from the studies
in Table 6 and pool them for a given population from multiple
studies under a model of homogeneity. When pooled, we found
no statistically significant difference between case and con-
trol values for the combined Asian data set (p value=0.541),
nor for the separate Chinese (p value=0.89) or Japanese (p
value=0.43) subsets (Table 7). The same lack of difference
was true when considering only NTG cases.
Pooled data on M98K:  We found no evidence of signifi-
cant difference between case and control frequencies for M98K
in our Asian, African, Hispanic, or Caucasian populations
(Table 8). Fuse and Alward reported statistically significant
evidence of association of M98K with OAG in the Japanese
population, although Alward indicated that this difference
becomes nonsignificant when adjusted for testing multiple
times. [11,17]. Other studies do not report a significant case-
control difference [11-24].
Previous studies supported our finding that M98K allele
frequences are much higher in populations of Asian (555/2818,
19.7%) or African (38/169, 22.5%) ancestries than in Cauca-
sian (179/3149, 5.7%) or Hispanic (2/61, 3.3%) populations
(Table 8 and Table 9). Thus, ancestry would be a significant
confounding variable when attempting to analyze data pooled
from different populations.
If we consider specific defined subpopulations, where
there should be less concern about ancestry serving as a con-
founding variable, then we are left with concerns about differ-
ences observed not just between but also within populations.
When we compared the different Asian studies using odds ra-
tios (Figure 3), the aggregate Asian data, the aggregate Japa-
nese data, the data produced by our study, and by the indi-
vidual studies of Umeda et al. [21], Fuse et al. [17], and Alward
et al. [11], we found each showed significant evidence of a
difference between cases and controls. When we evaluated
allele frequencies for the various Asian data sets, we saw dra-
matic differences in allele frequencies among the different stud-
ies (Figure 3, Table 8). Also, the control values showed much
greater variation among studies than the case values. The con-
trol values from some studies are higher than the case values
from other studies, even though within each separate study
the case frequencies are always higher than control frequen-
cies (Figure 3). With regard to our study, in which a small
number of samples came from diverse Asian regions, the ob-
served difference could be due to the limited case sample size,
differential representation of M98K within the Asian popula-
tion, case versus control status, or some combination of the
three.
The results of the Woolf test for heterogeneity indicated
that there was something noncomparable about the M98K find-
ings from a number of the studies that reported results for the
same populations (Table 9). In the case of the Japanese data
set, pooled data showed M98K frequencies of 18.2% (220/
1208) in cases versus 11.6% (77/661) in controls (p
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TABLE 4. FREQUENCY OF SEQUENCE VARIANTS THAT ALTER THE OPTN
PROTEIN SEQUENCE
Protein change    DNA change    Exon   Ancestry    Cases   Controls
--------------   ------------   ----   ---------   -----   --------
E50K             c.458 G>A        4    Hispanic    1/11     0/50
I88V             c.572 A>G        5    Caucasian   0/217    1/116
A99S             c.605 G>T        5    African     0/81     2/88
E322K            c.1274 G>A      10    African     1/81     6/88
E322K            c.1274 G>A      10    Caucasian   1/217    0/90
691Frameshift    691_692insAG     6    Caucasian   1/217    0/116
R545Q            c.1944 G>A      16    Asian       2/5      11/117
All case samples were screened and scored for each mutation listed.
Absence of a listing for one of the four control groups does not imply
that it was screened. Data for M98K appear in Table 5.
TABLE 5. FREQUENCY OF M98K IN FOUR POPULATIONS WITHIN OUR
COHORT
                                                                    Fisher’s
                                                                     exact
              Whole                             Total                 test
Ancestry    population   JOAG    POAG    NTG     OAG     Controls   p value
---------   ----------   ----   ------   ----   ------   --------   --------
Frequency of mutation in screened samples by population
African       38/169     3/14   14/63    1/4     18/81    20/88      1.0
Asian         32/122     1/2     1/1     1/2      3/5     29/117     0.112
Hispanic       2/62      0/3     1/7     0/1      1/11     1/50      0.331
Caucasian     22/336     3/32   11/159   0/26   14/217     8/116     1.0
Total         94/690     7/51   27/230   2/33   36/314    58/371
Percent of mutation in screened samples by population
African        22.5      21.4    22.2    25.0    22.2      22.7
Asian          26.2      50.0   100.0    50.0    60.0      24.8
Hispanic        3.2       0.0    14.3     0.0     9.1       2.0
Caucasian       6.5       9.4     6.9     0.0     6.5       6.9
Total           3.6       3.7     1.7     6.1     1.5       5.6
The total enumeration of both cases and controls is listed in the whole
population column. Cases are subdivided according to OAG type,
either JOAG, POAG, or NTG. A two-sided Fisher’s exact test p value
indicated no statistical significance for association between cases and
controls in each ancestry category. Woolf’s test for homogeneity
among the ancestry frequencies yielded a p value of 0.312, indicat-
ing that the ancestral subdivisions are statistically similar.
155value=0.0002), but results of the Woolf test led us to suspect
that we may be combining noncomparable data sets (p
value=0.046). In the case of the European data set, Fisher’s
exact test indicated that there was a statistically significant
difference between cases and controls (p value=0.001), but
again the Woolf test identified heterogeneity among the data
sets (p value=0.005; Table 9). When we pooled the world-
wide data from the entire set of published studies, we saw a
significant difference between cases and controls (p
value=0.00000004), but again, testing for heterogeneity indi-
cated that it may be invalid to pool these studies (Table 9; p
value=0.0018). Interestingly, if we removed data from the
Rezaie study [9], which indicated Caucasian controls but did
not specify its case population composition, the remaining
Caucasian data sets appeared to be homogeneous (p
value=0.512) and Fisher’s exact test indicated no significant
difference between case and control values (Table 9; p
value=0.072). Fewer studies distinguish observations for NTG
only. For those studies that provided data for NTG frequen-
cies, we saw that both the Japanese and European populations
showed homogeneity across studies. However, Fisher’s exact
testing of pooled studies showed opposing results between
Japanese (p value=0.00002) and European (p value=0.58)
populations.
The case versus control difference for the Hispanic data
are also intriguing, with M98K case values of 1/11 (9.1%)
and control values of 1/50 (2.0%). Our small Hispanic data
set was not well-powered for statistical testing, but this repre-
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TABLE 6. COMPARISON OF R545Q FREQUENCY IN DIFFERENT POPULATIONS
                                                                                            Fisher’s
                    OAG          Controls          Percent                 95% CI bounds     exact
               -------------   -------------   ---------------    Odds    ---------------    test
   Source      R545Q   Total   R545Q   Total   OAG    Controls   ratio    Lower    Upper    p value
------------   -----   -----   -----   -----   ----   --------   ------   -----   -------   --------
China
[14]             5      118      5      150     4.2     3.3       1.28    0.36      4.54     0.753
[15]            27      400     19      262     6.8     7.3       0.92    0.50      1.70     0.876
Japan
[11]            12      247      3       89     4.9     3.4       1.46    0.40      5.31     0.767
[16]            26      411     11      218     6.3     5.0       1.27    0.62      2.62     0.596
[17]             1      154      0      100     0.6     0.0       1.96*   0.08*    48.69*    1.000
[20]            20      313     10      196     6.4     5.1       1.27    0.58      2.77     0.700
[21]             3       83      4       58     3.6     6.9       0.51    0.11      2.35     0.446
Asia
[This study]     2        6     11      117    33.3     9.4       4.82    0.79     29.36    0.122
Europe
[This study]     0      217      -       -      0.0      -         -        -        -        -
[11]             0      650      0      162     0.0     0.0        -        -        -        -
[13]             0       27      0       94     0.0     0.0        -        -        -        -
[9]              1       46      0      100     2.2     0.0       6.63*   0.26*   165.80*   0.315
[22]             0      112      -       -      0.0      -         -        -        -        -
Africa
[This study]     0       81      0       90     0.0     0.0        -        -        -        -
India
[19]             6      200      0      200     3.0     0.0      13.40*   0.75*   239.49*   0.030
Mixed
[23]             0       86      0       80     0.0     0.0        -        -        -        -
[24]             1      114      3      187     0.9     1.6       0.54    0.06      5.28    1.000
The asterisks denote a calculation based on adding 0.5 to each cell in cases with a zero cell frequency, otherwise the value is nonexistent.
Lower and upper bounds refer to the individual study 95% confidence interval around the odds ratio for a fixed effects Mantel-Haenszel
model. Information from Leung et al. [35] were omitted because it duplicated that contained in Fan et al. [15]. Data from Toda et al. [37] were
omitted because it duplicated information contained in Tang et al. [20]. In the Europe category, only the data regarding Caucasians (Iowa and
Australia) in Alward et al. [11] were enumerated, while the reported cases with pigmentary, developmental, and exfoliative data were omitted.
156sented an initial view of a population under represented in
previous studies (Table 8). Given that our Hispanic data set
represented cross-continental cases from North, Central, and
South America, we have to wonder whether the apparent dif-
ferences in M98K allele frequences was simply due to small
sample size, or rather might be attributed to differential allele
frequencies correlated with geographic origins of samples
rather than case-control status.
DISCUSSION
 In our study of 314 individuals with OAG, we found 42 indi-
viduals with sequence variants predicted to alter the protein
coding sequence. This included three OPTN variants previ-
ously reported to be disease-causing variants-E50K,
691_692insAG, and R545Q, as well as the M98K variant pre-
viously reported as a risk factor [9].
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Figure 2. R545Q log odds ratios and allele frequences in Asian population studies.  A shows the odds ratios with 95% confidence interval bars
for individual Asian studies, and pooled results for Japan, China, and both in open angle glaucoma (OAG) cases versus controls. Odds ratios
and confidence intervals are fixed effect estimates resulting from the Mantel-Haenszel method. B shows the case (OAG, filled circle) and
control (open circle) proportion observed for each study. Total sample sizes are listed along the right-hand margin. None of the differences
between case and control frequencies are statistically significant in a comparison of the odds ratios (as readily observed from the odds ratio
confidence intervals) and frequencies of R545Q mutations in any of the Asian populations studied.
TABLE 7. AGGREGATE STATISTICAL SUMMARIES IN ASIAN POPULATIONS SCREENED FOR R545Q
                                                                                              Fisher’s
                Cases         Controls         Percent              95% CI bounds    Woolf     exact
            -------------   -------------   -------------   Odds    -------------    test       test
Ancestry    R545Q   Total   R545Q   Total   OAG   Control   ratio   Lower   Upper   p value   p value
---------   -----   -----   -----   -----   ---   -------   -----   -----   -----   -------   --------
China       32      518     24      412     6.2   5.8       0.98    0.57    1.70    0.648     0.89
Japan       62      1208    28      661     5.1   4.2       1.20    0.76    1.90    0.838     0.43
Asia        94      1726    52      1073    5.4   4.8       1.12    0.78    1.58    0.925     0.541
China-NTG   7       106     5       150     6.6   3.3       2.04    0.54    8.41    -         0.244
Japan-NTG   40      705     28      661     5.7   4.2       1.40    0.84    2.33    0.848     0.263
Results from computing the upper and lower 95% confidence interval bounds around the odds ratio indicate that none of the Asian divisions
are statistically different from an odds ratio of 1. The Woolf test for homogeneity indicates that across studies within each ancestry group the
odds ratios are statistically equivalent (i.e., homogeneous, because a p value less than 0.05 would indicate heterogeneity [25]). A two-sided
Fisher’s exact test on the pooled frequencies was computed for those instances when the Woolf test indicated homogeneity at the 0.05 level.
The ancestry groups are collated for China from Chen et al. [14] and Fan et al. [15]; and for Japan from Alward et al. [11], Funayama et al. [16],
Fuse et al. [17], Tang et al. [20], and Umeda et al. [21]. The Asia listing includes data pooled from the China and Japan categories. Only Fan
et al. [15] report on NTG for China.
157This is the second time the 691_692insAG mutation has
been reported. Both times it has been identified in case popu-
lations but not seen in controls. It is the first report of
691_692insAG in an individual of Russian Ashkenazi Jewish
ancestry, and ancestry is unavailable for the previously reported
case. Although OPTN defects were originally reported in a
population of primarily NTG cases, we found this variant in
an individual with modestly elevated IOP (22 mmHg). The
shift in the reading frame that it causes and the fact that it is
seen among cases but not controls suggests that it could be a
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TABLE 8. FREQUENCY OF M98K IN INDIVIDUALS FROM DIFFERENT POPULATIONS
                                                                                      Fisher’s
                  Cases         Controls        Percent               95% CI bounds    exact
               ------------   ------------   --------------   Odds    -------------     test
   Source      M98K   Total   M98K   Total   OAG    Control   ratio   Lower   Upper   p value
------------   ----   -----   ----   -----   ----   -------   -----   -----   -----   --------
China
[14]            26     118     22     150    22.0    14.7     1.64    0.88     3.08    0.148
[15]           129     400     81     281    32.3    28.8     1.18    0.84     1.64    0.355
Japan
[11]            51     247      8      89    20.6     9.0     2.63    1.20     5.80    0.014
[16]            81     411     36     218    19.7    16.5     1.24    0.81     1.91    0.389
[17]            25     154      5     100    16.2     5.0     3.68    1.36     9.97    0.009
[20]            51     313     27     196    16.3    13.8     1.22    0.74     2.02    0.527
[21]            12      83      1      58    14.5     1.7     9.63    1.22    76.31    0.149
Asia
[This study]     3       5     29     117    60.0    24.8     4.55    0.72    28.60    0.112
Europe
[This study]    13     217      8     116     6.0     6.9     0.86    0.34     2.14    0.814
[11]            46     650     10     162     7.1     6.2     1.16    0.57     2.35    1.000
[12]            22     315      3      95     7.0     3.2     2.30    0.67     7.87    0.224
[13]             2      27      3      94     7.4     3.2     2.43    0.38    15.33    0.310
[32]             9     200     10     200     4.5     5.0     0.90    0.36     2.25    1.000
[18]            11     237      5     110     4.6     4.5     1.02    0.35     3.02    1.000
[33]            11     170      1     100     6.5     1.0     6.85    0.87    53.87    0.036
[9]             23     169      9     422    13.6     2.1     7.23    3.27    15.98    0.000
[22]             7     105      7      93     6.7     7.5     0.88    0.3      2.6     1.000
Hispanic
[This study]     1      11      1      50     9.1     2.0     4.90    0.28    85.05    0.331
Africa
[This study]    18      81     20      88    22.2    22.7     0.97    0.47     2.00    1.000
India
[19]            22     200     11     200    11.0     5.5     2.12    1.00     4.51    0.068
[39]            10     220      0     100     4.5     0        inf    1.04     inf     0.034
Mixed
[38]            28     498     17     218     5.6     7.8     0.70    0.38     1.32    0.315
[36]            14     153      9     100     9.2     9.0     1.02    0.42     2.45    1.000
[23]             8      86      8      80     9.3    10.0     0.92    0.33     2.59    1.000
[24]            12     115      4     101    10.4     4.0     2.83    0.88     9.06    0.116
Under the fixed effects Mantel-Haenszel model, individual study 95% confidence interval bounds around the odds ratio are given. For com-
patibility with much of the published literature the two-sided Fisher’s exact test p values are given for each study. Although the presence of
M98K mutations in OAG cases appears to be statistically significant relative to controls, Alward et al. [11] reported that when multi-testing is
taken into account their result becomes nonsignificant. Information from Leung et al. [35] was omitted because it duplicated the information
contained in Fan et al. [15]. Data from Toda et al. [37] were omitted because they duplicated the observations contained in Tang et al. [20].
Pigmentary and exfoliative data were omitted from the Europe (Caucasians living in Iowa and Australia) samples reported by Alward et al.
[11]. Rezaie et al. [9] reported a p value=2.18-7.
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Figure 3. Studywise differences appear in Japanese populations when odds ratios and frequencies of M98K mutations are compared.  The left-
hand graph (A) shows the odds ratios with 95% confidence interval bars for individual Asian studies and pooled results for Japan, China, and
both in open angle glaucoma (OAG) cases versus controls. Odds ratios and confidence intervals are fixed effect estimates resulting from the
Mantel-Haenszel method. The right-hand graph (B) shows the case (OAG, filled circle) and control (open circle) proportions observed for
each study. Total sample sizes are listed along the right-hand margin. Larger samples have both narrower confidence intervals and shorter
distance between fractions observed for cases and controls. Studies inconsistently estimate the odds of OAG versus controls carrying an
M98K mutation, with larger studies (more than 400 total cases and controls) estimating no statistically significant difference. Other population
estimates are not shown, because, among the European population-based studies, only Rezaie’s study [9] showed a statistically significant
difference. The single study on India yielded a significant odds ratio, but no other comparable populations have been reported [19].
TABLE 9. AGGREGATE STATISTICAL SUMMARIES FOR POPULATIONS SCREENED FOR M98K
                                                                                                  Fisher’s
                 OAG          Controls         Percent                 95% CI bounds     Woolf     exact
             ------------   -------------  ---------------    Odds    ---------------    test       test
 Ancestry    M98K   Total   M98K   Total   OAG    Controls   ratio    Lower    Upper    p value   p value
----------   ----   -----   ----   -----   ----   --------   ------   -----   -------   -------   --------
China        155     518    103     431    29.9     23.9      1.26    0.94     1.70      0.354     0.04
Japan        220    1208     77     661    18.2     11.6      1.65    1.25     2.19      0.046       -
Asia         375    1726    180    1092    21.7     16.5      1.46    1.19     1.79      0.075     0.0006
Europe       131    1873     48    1276     7.0      3.8      1.87    1.31     2.66      0.005       -
Total        600    4871    277    3167    12.3      8.7      1.51    1.29     1.77      0.002       -
Japan-NTG    142     705     77     661    20.1     11.6      1.91    1.40     2.62      0.240      2E-5
Europe-NTG    28     371     24     544     7.5      4.4      1.77    0.97     3.24      0.149     0.58
Total-NTG    170    1076    101    1205    15.8      8.4      1.75    1.33     2.31      0.177      6E-8
The ancestry groups are collated for China: Chen et al. [14] and Fan et al. [15]; Japan: Alward et al. [11], Funayama et al. [16], Fuse et al. [17],
Tang et al. [20], and Umeda et al. [21]; Europe: Alward et al. [11], Aung et al. [12], Baird et al. [13], Jansson et al. [32], Melki et al. [18],
Rakhmanov et al. [33], Rezaie et al. [9], and Weisschuh et al. [22]. Asia is the pooling of the China and Japan categories. The total combines
all published studies from the lines above with the addition of Craig et al. [38], Hauser et al. [36], Mukhopadhyay et al. [19], Sripriya et al.
[39], Wiggs et al. [23], and Willoughby et al. [24]. The Europe-NTG group consists of the data from Alward et al. [11], Aung et al. [12], Baird
et al. [13], Rakhmanov et al. [33], and Weisschuh et al. [22]. Results from computing the upper and lower 95% confidence interval bounds
around the odds ratio indicate that some studies are statistically different than an odds ratio of 1. The Woolf test for homogeneity indicated that
across studies within each ancestry group which of the odds ratios were statistically equivalent (i.e., heterogeneity is indicated by a p value less
than 0.05 [25]). A two-sided Fisher’s exact test on the pooled frequencies is given for those instances when the Woolf test indicated homoge-
neity at the 0.05 level. When Rezaie et al. [9] data are excluded the Europe group, then the odds ratio becomes 1.33 with a 95% confidence
interval of (0.90, 1.98), Woolf p value of 0.512, and a Fisher’s exact test p value of 0.072.
159causative variant. However, if we combine data from all stud-
ies, we see it in 2/3677 cases (0.0005%) in the studies that
used protocols that would have detected it (all studies in Table
8 except Aung [12], Melki [18], and Wiggs [23]). Only a frac-
tion of the 2,270 controls from those studies screened the whole
sequence from all controls, so they would not have been highly
likely to detect this variant among the controls even if the
control frequency were equal to the case frequency. Thus, while
it is tempting to say that a variant seen only in two cases might
be causative, the available numbers can only support the con-
clusion that 691_692insAG event is a rare occurence.
We report here the first observation of the E50K change
in a Caucasian Hispanic individual. The observation of E50K
at a frequency of 0.3% in our cases is consistent with reports
of frequencies in OAG populations of 0.1% by Alward et al.
[11], 0.6% by Aung et al. [12], and 0.6% by Hauser et al. [36].
The NTG subset is reported to have E50K at a higher preva-
lence of 13.5% (7/52),1.5% (2/132), 1.5% (1/67), and 2.9%
(1/34) in studies by Rezaie et al. [9], Aung et al. [12], Hauser
et al. [36], and ourselves, respectively. Many other studies
found no evidence of this mutation, including reports of its
absence from 237 cases with Chinese ancestry [14,35] and
961 cases with Japanese ancestry [11,14,16,17,20,21,35,37],
which supports the supposition that this is a polymorphism
private to the Caucasian and Hispanic populations. Variation
in frequencies observed among studies may be affected by the
ancestry of the population, the fraction of the cohort with fa-
milial glaucoma, and differences in specific diagnoses included
in the study. Failure to see complete cosegregation of E50K
with glaucoma (i.e., we have one OAG case in a family lack-
ing the E50K mutation) raises questions about whether we are
observing a phenocopy or whether E50K is not the cause of
the glaucoma in this family.
Our data and the compiled evidence from more than a
dozen other studies support the idea that R545Q may be a
private polymorphism of Asian populations. Although our
Asian data set provides marginal evidence for a difference in
R545Q allele frequency between cases and controls, it is a
small population and the results are not statistically signifi-
cant. When we pooled our data with data from other studies
there did not appear to be any evidence to support a role for
R545Q as a disease causing variant.
We  found the M98K variant in all four populations
screened, but evaluation of all of the published studies leaves
unresolved the issue of whether or not M98K is a risk factor
for glaucoma. A similar conclusion was drawn by Craig et al.
[38] but they did not analyze the population (ancestry) struc-
ture of the data for the allele. Several studies find evidence for
association, while others do not. Evaluation of the published
data in addition to our own indicates that there is considerable
variation in allele frequencies, not only among populations,
but also within populations. This variant is found in Asian and
African populations at more than twice the frequency seen in
Caucasian and Hispanic populations. Comparison of findings
from different studies indicates large variations in allele fre-
quencies in different study populations within Japanese (MH
p value=0.00038) and Chinese (MH p value=0.118) popula-
tions (Table 9). The case-control difference is much smaller
within Caucasian or African populations (Figure 3), and data
on Caucasian populations show less variation between stud-
ies than the data on Japanese and Chinese populations (Table
9, Figure 3).
There are a number of confounding factors that might con-
tribute to the observed variability of allele frequency between
Asian populations. Differential allele frequencies within a
population could result from founder effects. At this point,
there is not enough information available regarding origins of
the different subpopulations (Table 10) to allow for evalua-
tion of the likelihood of a founder effect. There appears to be
a correlation between total sample size and the difference be-
tween case and control frequencies (Figure 2), although the
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TABLE 10. M98K POPULATION DATA SOURCES AND SCREENING
METHODS ORDERED BY ANCESTRY
                   Recruitment
                    locations
   Source          (population)          Methodology                   Notes
------------   --------------------   ------------------   ------------------------------
   China
[14]           China-Beijing          SSCP->sequencing
[15]           China-Hong Kong        PCR and
                                      HTCSGE->sequencing
   Japan
[11]           Japan-Gifu             SSCP->sequencing
[16]           Japan-Tokyo,           PCR-RFLP
               Kumamoto, Hamamatsu,
               Hiroshima, Niigata
[17]           Japan-Miyagi           PCR->sequencing
[20]           Japan-Yamanashi        SSCP->sequencing
[21]           Japan-Okayama City     sequencing
   Asia (other than China and Japan)
[This study]   USA-Michigan           PCR->sequencing
               (Korean, Chinese,
               Filipino)
   Europe
[This study]   USA-Michigan           PCR->sequencing      Caucasian
[11]           Australia-Melbourne,   SSCP->sequencing     Australian samples
               Adelaide, USA-Iowa                          areCaucasian (D. Mackey,
                                                           personal report), Iowa
                                                           population >91% Caucasian
                                                           according to the State Data
                                                           Center of Iowa
[12]           England-London         PCR-RFLP             Caucasian
[13]           Australia-New South    PCR-RFLP             mostly Caucasian
               Wales
[32]           Sweden-Uppsala and     DHPLC, PCR,
               Tierps                 SNaPshot
[18]           France-Paris           PCR-RFLP             French and Moroccan Caucasians
[33]           Russia-St.             SSCP, PCR
               Petersburg
[9]            USA-Chicago,           PCR->sequencing      Unspecified cases with
               Connecticut, New       and                  Caucasian controls
               Haven,UK-London,       SSCP->sequencing
               Canada-Toronto
[22]           Germany-Tuebingen,     PCR-RFLP, DHPLC
               Wuerzburg
   Hispanic
[This study]   USA-Michigan,          PCR->sequencing
               Florida, Mexico,
               Panama, Peru, Chile,
               Paraguay
   Africa
[This study]   USA-Michigan, Ghana-   PCR->sequencing      African American and African
               Accra, Sunyani
   India
[19]           India-Hyperabad,       SSCP->sequencing,
               Kolkata                DHPLC, PCR--RFLP
[39]           India-Chennai          PCR->sequencing,
                                      RFLP
   Mixed
[38]           Australia/Tasmania     PCR-RFLP
[36]           USA-New England area   PCR->sequencing,     about 90% Caucasian
                                      DHPLC
[23]           USA-Massachusetts,     PCR->sequencing      about 90% Caucasian
               North Carolina
[24]           Canada-Toronto         PCR-RFLP
The following methodologies were used to screen samples for vari-
ants. We omitted two studies: Wang et al. [40], a Filipino population,
and Forsman et al. [34], a population from south Finland, because
they are small family-based studies without population data. SSCP:
single-strand conformation polymorphism. DHPLC: denaturing high-
performance liquid chromatography. HTCSGE: High throughput con-
formation sensitive gel electrophoresis. RFLP: Restriction Fragment
Length Polymorphisms.
160published studies seem to be adequately powered (for Fisher’s
exact test, the power, or probability to reject the null hypoth-
esis when it is true, is 0.76 for the parameters π1=0.2, π2=0.1,
where each sample size is 200 and α=0.05). An alternative
confounding factor could be the result of the different screen-
ing techniques applied (Table 10); however, there is no obvi-
ous correlation of high allele frequencies with one screening
approach and low allele frequencies with a different technique.
Selective under-representation of an allele in a data set rela-
tive to the actual allele frequency could result if M98K were
in linkage disequilibrium with a neighboring polymorphism
contained within the sequence of a primer used in amplifica-
tion or sequencing in some studies, but not others. Some of
the papers do not present the primer sequences and the avail-
able primer sequence data do not provide support for this idea.
Additional contributions to variability between studies could
include differences in diagnostic inclusion and exclusion cri-
teria and fraction of familial glaucoma within each cohort.
Thus, the extant data do not allow us to distinguish between
technical, ascertainment and demographic models for the ob-
served differences in M98K allele frequencies between dif-
ferent studies of the same population.
An alternative approach to evaluation of whether the
M98K allele is involved in glaucoma is through the study of
cosegregation in families. Wiggs et al. [23] reported lack of
cosegregation in families. An accompanying population-based
portion of that study [23] also failed to find association of
M98K with glaucoma in a population of mostly European
ancestry.
One alternative explanation for why some studies find
association, yet others do not, might be that there is a valid
statistical difference between the case and control populations
but that the M98K allele is actually associated with some other
variable that differs between cases and controls, or has been
excluded from cases but not controls. An obvious example of
this would be IOP. The Rezaie et al. study [9] looked at mostly
NTG families, while there was a lot of variation in the extent
to which NTG was represented in the different populations in
the other studies. If M98K is actually responsible for reduc-
ing IOP, or for preventing the rise of IOP, but is not actually
causing glaucoma, then we would expect exclusion of indi-
viduals with elevated IOP from the cases would bias the M98K
frequency in the cases as compared to the controls even if
M98K were not actually causing glaucoma. Melki et al. [18]
offered the view that M98K is associated with lower IOP. In
our data set we found that cases with the M98K mutation had
known maximum IOP values ranging from 16 mmHg to 55
mmHg (mean=29.6 mmHg) while those who lacked the M98K
mutation had maximum recorded IOP values ranging from 14
mmHg in an NTG case up to 77 mmHg (mean=29.9 mmHg).
Thus, in our data set there was no obvious difference in maxi-
mum known IOP between those with and those without M98K.
The original report by Rezaie provided apparently com-
pelling statistical evidence that M98K is a glaucoma risk fac-
tor with a p value of 2.18x10-7. The other studies that found
any support for M98K association with glaucoma found only
weak evidence of this association. It remains unclear what the
differences are between the studies that could account for the
differences in study outcome. One key issue for M98K ap-
pears to be the great variability of allele frequency reported in
different studies and different populations. This would be a
problem if the case population in the Rezaie et al. study [9]
contained multiple populations or an admixed population that
self-identified as Caucasian. In the Rezaie et al. study [9], both
E50K, an apparently private Caucasian polymorphism, and
R545Q, an apparently private Asian polymorphism, were in
the same study cohort. While this could mean that their
undescribed case population was a mixed race group, it is also
the kind of thing that can happen in a fairly admixed urban
population when using self identification as the basis for ap-
plying racial/ethnic classification, even when setting out to
identify a relatively homogeneous population. Thus, there is
the possibility that the Rezaie et al. study [9] outcome differs
from the others because of differences in diagnostic inclusion
and exclusion criteria or other unidentified factors, but it could
also be the result of studying an allele that varies significantly
between and within populations - something that can happen
even when making efforts to carry out adequate matching of
cases and controls.
Thus the findings on M98K are currently contradictory,
with some studies finding association and other studies find-
ing no support for association, and with the differences in study
outcome not assorting according to population or technology
used. Because there are such substantial differences in allele
frequencies between the different studies and between and
within populations, it is likely that a final resolution of this
question will require the following: The screening to take place
by technologies selected for precision rather than high through-
put; the study be adequately powered; matching of cases and
controls for ancestry be highly rigorous and matched for sub-
populations rather than simply matching for one of a handful
of racial or ethnic categories; inclusion and exclusion criteria
be carefully defined, that tests for association with associated
variables such as IOP be carried out in addition to tests for
association with the primary glaucoma status variable; and
population substructure analysis be included in the analysis to
help deal with apparent differences within populations that
can be difficult to control.
This study has contibuted additional evidence of associa-
tion of OPTN E50K with glaucoma, and reported an addi-
tional instance of the 691_692insAG sequence variant. We
have also provided new information on OPTN in populations
of African and Hispanic ancestry. Evaluation of data from more
than a dozen studies indicated no association of R545Q with
glaucoma in most populations. Combined analysis of more
than a dozen studies suggests that M98K is associated with
NTG in Asian, but not Caucasian study populations, but these
results must be interpreted with great caution because of the
large differences in allele frequencies between and within
populations.
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